866-997-4948(US-Canada Toll Free)

Global Urological Cancer Therapeutics Drugs Sales Market Report 2017

Published By :

QYResearch

Published Date : Feb 2017

Category :

Cancer

No. of Pages : 127 Pages

Notes:
Sales, means the sales volume of Urological Cancer Therapeutics Drugs
Revenue, means the sales value of Urological Cancer Therapeutics Drugs

This report studies sales (consumption) of Urological Cancer Therapeutics Drugs in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.

Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Urological Cancer Therapeutics Drugs in these regions, from 2011 to 2021 (forecast), like
United States
China
Europe
Japan
Southeast Asia
India
Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Split by applications, this report focuses on sales, market share and growth rate of Urological Cancer Therapeutics Drugs in each application, can be divided into
Hospital
Medical Research Laboratory
Others

Table of Contents

Global Urological Cancer Therapeutics Drugs Sales Market Report 2017
1 Urological Cancer Therapeutics Drugs Overview
1.1 Product Overview and Scope of Urological Cancer Therapeutics Drugs
1.2 Classification of Urological Cancer Therapeutics Drugs
1.2.1 Xofigo (radium Ra 223 dichloride)
1.2.2 Jevtana (cabazitaxel)
1.2.3 Inlyta (axitinib)
1.2.4 Votrient (pazopanib hydrochloride)
1.2.5 Sutent (sunitinib malate)
1.2.6 Zytiga (abiraterone acetate)
1.2.7 Xtandi (enzalutamide)
1.2.8 Opdivo (nivolumab)
1.2.9 Provenge (sipuleucel-T)
1.3 Application of Urological Cancer Therapeutics Drugs
1.3.1 Hospital
1.3.2 Medical Research Laboratory
1.3.3 Others
1.4 Urological Cancer Therapeutics Drugs Market by Regions
1.4.1 United States Status and Prospect (2012-2022)
1.4.2 China Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 Japan Status and Prospect (2012-2022)
1.4.5 Southeast Asia Status and Prospect (2012-2022)
1.4.6 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value and Volume) of Urological Cancer Therapeutics Drugs (2012-2022)
1.5.1 Global Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2022)
1.5.2 Global Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2022)

2 Global Urological Cancer Therapeutics Drugs Competition by Manufacturers, Type and Application
2.1 Global Urological Cancer Therapeutics Drugs Market Competition by Manufacturers
2.1.1 Global Urological Cancer Therapeutics Drugs Sales and Market Share of Key Manufacturers (2012-2017)
2.1.2 Global Urological Cancer Therapeutics Drugs Revenue and Share by Manufacturers (2012-2017)
2.2 Global Urological Cancer Therapeutics Drugs (Volume and Value) by Type
2.2.1 Global Urological Cancer Therapeutics Drugs Sales and Market Share by Type (2012-2017)
2.2.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Type (2012-2017)
2.3 Global Urological Cancer Therapeutics Drugs (Volume and Value) by Regions
2.3.1 Global Urological Cancer Therapeutics Drugs Sales and Market Share by Regions (2012-2017)
2.3.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Regions (2012-2017)
2.4 Global Urological Cancer Therapeutics Drugs (Volume) by Application

3 United States Urological Cancer Therapeutics Drugs (Volume, Value and Sales Price)
3.1 United States Urological Cancer Therapeutics Drugs Sales and Value (2012-2017)
3.1.1 United States Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2017)
3.1.2 United States Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2017)
3.1.3 United States Urological Cancer Therapeutics Drugs Sales Price Trend (2012-2017)
3.2 United States Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturers
3.3 United States Urological Cancer Therapeutics Drugs Sales and Market Share by Type
3.4 United States Urological Cancer Therapeutics Drugs Sales and Market Share by Application

4 China Urological Cancer Therapeutics Drugs (Volume, Value and Sales Price)
4.1 China Urological Cancer Therapeutics Drugs Sales and Value (2012-2017)
4.1.1 China Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2017)
4.1.2 China Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2017)
4.1.3 China Urological Cancer Therapeutics Drugs Sales Price Trend (2012-2017)
4.2 China Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturers
4.3 China Urological Cancer Therapeutics Drugs Sales and Market Share by Type
4.4 China Urological Cancer Therapeutics Drugs Sales and Market Share by Application

5 Europe Urological Cancer Therapeutics Drugs (Volume, Value and Sales Price)
5.1 Europe Urological Cancer Therapeutics Drugs Sales and Value (2012-2017)
5.1.1 Europe Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2017)
5.1.2 Europe Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2017)
5.1.3 Europe Urological Cancer Therapeutics Drugs Sales Price Trend (2012-2017)
5.2 Europe Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturers
5.3 Europe Urological Cancer Therapeutics Drugs Sales and Market Share by Type
5.4 Europe Urological Cancer Therapeutics Drugs Sales and Market Share by Application

6 Japan Urological Cancer Therapeutics Drugs (Volume, Value and Sales Price)
6.1 Japan Urological Cancer Therapeutics Drugs Sales and Value (2012-2017)
6.1.1 Japan Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2017)
6.1.2 Japan Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2017)
6.1.3 Japan Urological Cancer Therapeutics Drugs Sales Price Trend (2012-2017)
6.2 Japan Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturers
6.3 Japan Urological Cancer Therapeutics Drugs Sales and Market Share by Type
6.4 Japan Urological Cancer Therapeutics Drugs Sales and Market Share by Application
7 Southeast Asia Urological Cancer Therapeutics Drugs (Volume, Value and Sales Price)
7.1 Southeast Asia Urological Cancer Therapeutics Drugs Sales and Value (2012-2017)
7.1.1 Southeast Asia Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2017)
7.1.2 Southeast Asia Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2017)
7.1.3 Southeast Asia Urological Cancer Therapeutics Drugs Sales Price Trend (2012-2017)
7.2 Southeast Asia Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturers
7.3 Southeast Asia Urological Cancer Therapeutics Drugs Sales and Market Share by Type
7.4 Southeast Asia Urological Cancer Therapeutics Drugs Sales and Market Share by Application
8 India Urological Cancer Therapeutics Drugs (Volume, Value and Sales Price)
8.1 India Urological Cancer Therapeutics Drugs Sales and Value (2012-2017)
8.1.1 India Urological Cancer Therapeutics Drugs Sales and Growth Rate (2012-2017)
8.1.2 India Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2012-2017)
8.1.3 India Urological Cancer Therapeutics Drugs Sales Price Trend (2012-2017)
8.2 India Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturers
8.3 India Urological Cancer Therapeutics Drugs Sales and Market Share by Type
8.4 India Urological Cancer Therapeutics Drugs Sales and Market Share by Application

9 Global Urological Cancer Therapeutics Drugs Manufacturers Analysis
9.1 Novartis
9.1.1 Company Basic Information, Manufacturing Base and Competitors
9.1.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.1.2.1 Xofigo (radium Ra 223 dichloride)
9.1.2.2 Jevtana (cabazitaxel)
9.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.1.4 Main Business/Business Overview
9.2 Pfizer
9.2.1 Company Basic Information, Manufacturing Base and Competitors
9.2.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.2.2.1 Xofigo (radium Ra 223 dichloride)
9.2.2.2 Jevtana (cabazitaxel)
9.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.2.4 Main Business/Business Overview
9.3 Johnson & Johnson
9.3.1 Company Basic Information, Manufacturing Base and Competitors
9.3.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.3.2.1 Xofigo (radium Ra 223 dichloride)
9.3.2.2 Jevtana (cabazitaxel)
9.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.3.4 Main Business/Business Overview
9.4 AstraZeneca
9.4.1 Company Basic Information, Manufacturing Base and Competitors
9.4.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.4.2.1 Xofigo (radium Ra 223 dichloride)
9.4.2.2 Jevtana (cabazitaxel)
9.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.4.4 Main Business/Business Overview
9.5 Astellas
9.5.1 Company Basic Information, Manufacturing Base and Competitors
9.5.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.5.2.1 Xofigo (radium Ra 223 dichloride)
9.5.2.2 Jevtana (cabazitaxel)
9.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.5.4 Main Business/Business Overview
9.6 Bristol-Myers Squibb
9.6.1 Company Basic Information, Manufacturing Base and Competitors
9.6.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.6.2.1 Xofigo (radium Ra 223 dichloride)
9.6.2.2 Jevtana (cabazitaxel)
9.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.6.4 Main Business/Business Overview
9.7 Abbott Laboratories
9.7.1 Company Basic Information, Manufacturing Base and Competitors
9.7.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.7.2.1 Xofigo (radium Ra 223 dichloride)
9.7.2.2 Jevtana (cabazitaxel)
9.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.7.4 Main Business/Business Overview
9.8 Celgene Corporation
9.8.1 Company Basic Information, Manufacturing Base and Competitors
9.8.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.8.2.1 Xofigo (radium Ra 223 dichloride)
9.8.2.2 Jevtana (cabazitaxel)
9.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.8.4 Main Business/Business Overview
9.9 Dendreon Corporation
9.9.1 Company Basic Information, Manufacturing Base and Competitors
9.9.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.9.2.1 Xofigo (radium Ra 223 dichloride)
9.9.2.2 Jevtana (cabazitaxel)
9.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.9.4 Main Business/Business Overview
9.10 Ferring Pharmaceuticals
9.10.1 Company Basic Information, Manufacturing Base and Competitors
9.10.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification
9.10.2.1 Xofigo (radium Ra 223 dichloride)
9.10.2.2 Jevtana (cabazitaxel)
9.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.10.4 Main Business/Business Overview
9.11 GlaxoSmithKline plc
9.12 Indevus Pharmaceuticals Inc
9.13 Ipsen
9.14 Roche Healthcare
9.15 Sanofi S.A.

10 Urological Cancer Therapeutics Drugs Maufacturing Cost Analysis
10.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis
10.1.1 Key Raw Materials
10.1.2 Price Trend of Key Raw Materials
10.1.3 Key Suppliers of Raw Materials
10.1.4 Market Concentration Rate of Raw Materials
10.2 Proportion of Manufacturing Cost Structure
10.2.1 Raw Materials
10.2.2 Labor Cost
10.2.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
10.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
11.1 Urological Cancer Therapeutics Drugs Industrial Chain Analysis
11.2 Upstream Raw Materials Sourcing
11.3 Raw Materials Sources of Urological Cancer Therapeutics Drugs Major Manufacturers in 2015
11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
12.1 Marketing Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.1.3 Marketing Channel Development Trend
12.2 Market Positioning
12.2.1 Pricing Strategy
12.2.2 Brand Strategy
12.2.3 Target Client
12.3 Distributors/Traders List

13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes Threat
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs/Customer Preference Change
13.3 Economic/Political Environmental Change

14 Global Urological Cancer Therapeutics Drugs Market Forecast (2017-2022)
14.1 Global Urological Cancer Therapeutics Drugs Sales, Revenue and Price Forecast (2017-2022)
14.1.1 Global Urological Cancer Therapeutics Drugs Sales and Growth Rate Forecast (2017-2022)
14.1.2 Global Urological Cancer Therapeutics Drugs Revenue and Growth Rate Forecast (2017-2022)
14.1.3 Global Urological Cancer Therapeutics Drugs Price and Trend Forecast (2017-2022)
14.2 Global Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast by Regions (2017-2022)
14.2.1 United States Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.2 China Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.3 Europe Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.4 Japan Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.5 Southeast Asia Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.6 India Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.3 Global Urological Cancer Therapeutics Drugs Sales, Revenue and Price Forecast by Type (2017-2022)
14.4 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2017-2022)

15 Research Findings and Conclusion

16 Appendix
Methodology
Analyst Introduction
Data Source


Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *